U.S. Markets close in 3 hrs 38 mins
  • S&P 500

    4,289.76
    +9.61 (+0.22%)
     
  • Dow 30

    33,882.63
    +121.58 (+0.36%)
     
  • Nasdaq

    13,093.89
    +46.70 (+0.36%)
     
  • Russell 2000

    2,013.10
    -3.52 (-0.17%)
     
  • Crude Oil

    88.61
    -3.48 (-3.78%)
     
  • Gold

    1,794.70
    -20.80 (-1.15%)
     
  • Silver

    20.24
    -0.46 (-2.24%)
     
  • EUR/USD

    1.0177
    -0.0080 (-0.7836%)
     
  • 10-Yr Bond

    2.7840
    -0.0650 (-2.28%)
     
  • Vix

    19.90
    +0.37 (+1.89%)
     
  • GBP/USD

    1.2071
    -0.0068 (-0.5601%)
     
  • USD/JPY

    133.2370
    -0.2430 (-0.1820%)
     
  • BTC-USD

    24,250.16
    -259.49 (-1.06%)
     
  • CMC Crypto 200

    576.54
    -14.23 (-2.41%)
     
  • FTSE 100

    7,509.15
    +8.26 (+0.11%)
     
  • Nikkei 225

    28,871.78
    +324.80 (+1.14%)
     

LAWSUITS FILED AGAINST MPLN, CCXI and ATER - Jakubowitz Law Pursues Shareholders Claims

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / May 26, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Multiplan Corporation F/K/A Churchill Capital Corp. Iii (NYSE: MPLN)

CONTACT JAKUBOWITZ ABOUT MPLN:
https://claimyourloss.com/securities/multiplan-corporation-f-k-a-churchill-capital-corp-iii-loss-submission-form/?id=16230&from=1

Class Period : July 12, 2020 - November 10, 2020

Lead Plaintiff Deadline : June 7, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) MultiPlan was losing tens of millions of dollars in sales and revenues to Naviguard, a competitor created by one of MultiPlan's largest customers, UnitedHealthcare, which threatened up to 35% of the Company's sales and 80% of its levered cash flows by 2022; (b) sales and revenue declines in the quarters leading up to the Merger were not due to "idiosyncratic" customer behaviors as represented, but rather due to a fundamental deterioration in demand for MultiPlan's services and increased competition, as payors developed competing services and sought alternatives to eliminating excessive healthcare costs; (c) MultiPlan was facing significant pricing pressures for its services and had been forced to materially reduce its take rate in the lead up to the Merger by insurers, who had expressed dissatisfaction with the price and quality of MultiPlan's services and balanced billing practices, causing the Company's to cut its take rate by up to half in some cases; (d) as a result of (a)-(c) above, MultiPlan was set to continue to suffer from revenues and earnings declines, increased competition and deteriorating pricing dynamics following the Merger; (e) as a result of (a)-(d) above, MultiPlan was forced to seek continued revenue growth and to improve its competitive positioning through pricey acquisitions, including through the purchase of HST for $140 million at a premium price from a former MultiPlan executive only one month after the Merger; and (f) as a result of (a)-(e) above, Churchill III investors had grossly overpaid for the acquisition of MultiPlan in the Merger, and MultiPlan's business was worth far less than represented to investors.

ChemoCentryx, Inc. (NASDAQ:CCXI)

CONTACT JAKUBOWITZ ABOUT CCXI:
https://claimyourloss.com/securities/chemocentryx-inc-loss-submission-form/?id=16230&from=1

Class Period : November 26, 2019 - May 3, 2021

Lead Plaintiff Deadline : July 6, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx's New Drug Application ("NDA") for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

Aterian, Inc. (NASDAQ:ATER)

CONTACT JAKUBOWITZ ABOUT ATER:
https://claimyourloss.com/securities/aterian-inc-loss-submission-form/?id=16230&from=1

Class Period : December 1, 2020 - May 3, 2021

Lead Plaintiff Deadline : July 12, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's organic growth is plummeting; (ii) the Company's recent, self-lauded acquisitions were overpayments for flawed assets from questionable sources; (iii) Aterian's purported artificial intelligence software is a flawed product that lacks customer interest; (iv) Aterian uses rebate programs and paid or artificial reviews to pump up their product offerings; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law



View source version on accesswire.com:
https://www.accesswire.com/649282/LAWSUITS-FILED-AGAINST-MPLN-CCXI-and-ATER--Jakubowitz-Law-Pursues-Shareholders-Claims